Rentschler Biotechnologie extends capacities for mammalian cell culture manufacturing
The modern, state-of-the-art 2,500 L bioreactor is designed such that batch, fed-batch, or perfusion cell culture processes can be run. Protein purification is performed in two suites for pre- and post-virus inactivation, respectively.
Using its modern GMP production suites, Rentschler Biotechnologie offers its customers comprehensive services "from gene to drug product". It is able to develop tailored solutions for each customer through all phases of development and production. Due to its "preferred partnership" agreement with Boehringer Ingelheim, customers requiring higher production capacities than that offered by Rentschler, receive easy access to Boehringer's large-scale bioreactor volumes of up to 15,000 L.
The global market for biopharmaceutical products is growing constantly and rapidly. As a consequence, since 2002, Rentschler Biotechnologie has invested more than 70 million Euros to enhance its production capacities. Rentschler has thus consolidated its position as a contract manufacturing organization (CMO) for the production of biopharmaceuticals and is now one of three leading European CMOs in this market segment. Since 2001 the number of employees has grown three-fold up to the present 350.
Rentschler Biotechnologie GmbH
RENTSCHLER Biotechnologie GmbH is an internationally operating contract organisation with many years of experience in the development, production and registration of drug products based on biopharmaceutical drug substances. The range of services of RENTSCHLER Biotechnologie GmbH also comprises the sterile filling of pre-filled syringes and injection vials. In Germany, the company employs more than 400 people.
The company RENTSCHLER, founded in 1927, concentrates its activities on the business sector biotechnology. RENTSCHLER Biotechnologie GmbH is a subsidiary of the medium-sized family-owned business Dr. RENTSCHLER Holding GmbH & Co. KG headquartered Laupheim, Baden-Wurttemberg, Germany.